Background Ticagrelor is an oral antiplatelet drug that can reversibly bind to the platelet
P2Y12 receptor. Ticagrelor is metabolized mainly by CYP3A4 and produces a rapid blood …

Myocardial infarction (MI) is the leading cause of morbidity and mortality worldwide. Despite
extensive efforts to provide early diagnosis and adequate treatment regimens, detection of …

Patients with severe infections and a pre-existing indication for antithrombotic therapy, ie
antiplatelet agents, anticoagulant drugs, or their combinations, require integrated clinical …

The pathological mechanism of neuropathic pain is complex, which seriously affects the
physical and mental health of patients, and its treatment is also difficult. The role of G protein …

The G protein-coupled P2Y12 receptor (P2Y12R) was cloned in platelets and found to play
a key role in maintaining platelet function in hemostasis and thrombosis, and these effects …

Metabolite identification plays a critical role in the phases during drug development. Drug
metabolites can contribute to efficacy, toxicity, and drug-drug interaction. Thus, the correct …

Purpose This study aims to assess the association between body mass index (BMI) and
platelet reactivity in STEMI patients treated with oral 3rd generation P2Y12 inhibitors …

The existence of purinergic signaling—the idea that almost all cells of the animal/human
organism are able to communicate with each other via extracellular purines—was proposed …

Dual antiplatelet therapy (DAPT), consisting of the combination of aspirin and an inhibitor of
the platelet P2Y12 receptor for ADP, remains among the most investigated treatments in …

Dual antiplatelet therapy (DAPT) has been the mainstay treatment to reduce ischemic
events, such as myocardial infarction or stroke, in patients with coronary artery disease …